Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals-Reference-Cited by-同舟云学术

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

Published:2021-06-28 Issue:1 Volume:15 Page:131-143
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Anderson Sarah-Jane^ORCID,Murray Miranda,Cella David,Grossberg Robert,Hagins Debbie,Towner William,Wang Marcia,Clark Andrew,Pierce Amy,Llamoso Cyril,Ackerman Peter,Lataillade Max

Funder

ViiV Healthcare

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40271-021-00534-y.pdf

Reference32 articles.

1. Palella FJ Jr, Delaney KM, Moorman AC, et al, and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–60.

2. Brown J, Chien C, Timmins P, et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci. 2013;102(6):1742–51.

3. Langley DR, Kimura SR, Sivaprakasam P, et al. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins. 2015;83(2):331–50.

4. Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64(1):7–15.

5. Nowicka-Sans B, Gong Y-F, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012;56(7):3498–507.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05

2. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir;BMC Infectious Diseases;2024-02-23

3. Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study;Contemporary Clinical Trials Communications;2022-08

4. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy;Drug Design, Development and Therapy;2022-01

5. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?;Cancers;2021-10-10